title: Management of acute myocardial infarction in Auckland.
abstract: OBJECTIVE
  To analyse the utilisation of therapies in coronary care units for patients with acute myocardial infarction.
  
  
  METHODS
  An evaluation form was completed prospectively by a designated nurse in each coronary care unit of the four Auckland hospitals in 1993.
  
  
  RESULTS
  One thousand and eighty one patients who were admitted with definite or probable acute myocardial infarction had a coronary care unit stay of 63.4 (SD 49.3) hours, and hospital stay of 7.3 (5.1) days. The mortality for definite myocardial infarction was 13.7% (< 70 years 7.1%). Coronary angiography was performed on 10% of patients during their hospital admission, and 4.9% underwent revascularisation. Thrombolytic therapy was administered to 52% (495/948) of patients with definite infarction and 4% had contraindications. Patients aged > or = 70 years (47% vs 55% p = 0.02) or diabetics (46% vs 56%, p = 0.04) were less likely to receive thrombolysis. The utilisation of aspirin and oral beta-blockers was 86% and 40%, respectively, in patients with definite infarction and both were used less frequently in patients > or = 70 years. Intravenous beta-blockers were administered to < 1% of patients. Angiotensin converting enzyme (ACE) inhibitors were prescribed in 21%, intravenous or long acting nitrates in 41% and calcium antagonists in 14%; the latter two therapies were used more frequently in patients > or = 70 years. There was no evidence of gender or ethnic bias for either investigation or treatment.
  
  
  CONCLUSIONS
  On the basis of results of recent clinical trials, there may be under utilisation of some treatments for acute myocardial infarction including aspirin, thrombolytic therapy, beta-blockers and ACE inhibitors, while calcium antagonists may be over used.
authors.affiliation: Coronary Care Unit, Auckland Hospital.
authors.forename: J
authors.initials: J
authors.lastname: French
authors.forename: B
authors.initials: B
authors.lastname: Williams
authors.forename: H
authors.initials: H
authors.lastname: Hart
authors.forename: K
authors.initials: K
authors.lastname: Woo
authors.forename: L
authors.initials: L
authors.lastname: Wang
authors.forename: J
authors.initials: J
authors.lastname: Grant
authors.forename: C
authors.initials: C
authors.lastname: Ingram
authors.forename: P
authors.initials: P
authors.lastname: O'Brien
authors.forename: J
authors.initials: J
authors.lastname: Poole
authors.forename: N
authors.initials: N
authors.lastname: Sharpe
authors.forename: M
authors.initials: M
authors.lastname: Williams
authors.forename: H
authors.initials: H
authors.lastname: White
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D003325:Coronary Care Units; D005260:Female; D006801:Humans; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000628:therapy*; D009520:New Zealand; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011446:Prospective Studies; D015912:Thrombolytic Therapy / Q000706:statistics & numerical data
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000889:Anti-Arrhythmia Agents; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin